Regeneron Pharmaceuticals announced Saturday promising early results with odronextamab, an experimental bispecific antibody therapy for diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer impacting the lymphatic system [[1]]. The ongoing clinical trial demonstrates a 100% complete response rate in a small cohort of patients receiving the treatment as an initial therapy, offering a potential new option for those with limited alternatives [[3]]. Odronextamab works by uniquely enlisting the body’s own immune system to target and destroy cancer cells [[2]].
A new experimental cancer treatment from Regeneron Pharmaceuticals is showing promising results, even leading to the disappearance of cancer in patients with blood cancer who had not previously received treatment, the company announced Saturday, November 18.
The treatment, called odronextamab, is being studied in a clinical trial involving 22 patients. Researchers are evaluating its safety and effectiveness as an initial therapy for patients with diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood cancer that affects the lymphatic system – a network of tissues and vessels crucial for immune function.
Odronextamab belongs to a class of therapies known as bispecific antibodies. These antibodies are engineered to simultaneously bind to both cancer cells and immune cells, effectively bringing them together so the body’s own immune system can target and destroy the cancer. This approach represents a growing area of innovation in cancer treatment.
According to Regeneron, patients who received a 160 milligram dose of the treatment combination achieved a 100% complete response rate. This high response rate suggests the therapy could offer a significant benefit to patients with limited treatment options.
Diffuse large B-cell lymphoma is a fast-growing cancer that develops in the lymphatic system, impacting the body’s ability to fight infection. The disease involves changes in B cells, a type of white blood cell. Early and effective treatment is critical for improving outcomes in patients with this aggressive cancer.
“A portion of our focus here at Regeneron is on developing bispecific medicines that are highly potent and don’t require a heavy additional combination of drugs to be incorporated, because their activity is so strong on its own,” said Afia Choudhury, Global Program Head at Regeneron.
